GPCRs are involved in a variety of physiological and pathophysiological processes. So far, much effort has been made on anti-GPCR drug discovery with a focus on the development of small molecules and monoclonal antibodies for the treatment of cancer, infection, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies directed against GPCRs were identified in various diseases associated with pathogenesis, uncovering a potential new field of therapeutic intervention. Thus, the aim of this journal is to combine the current knowledge on the role of GPCRs in different pathologies, their mode of action and state-of-the-art research techniques to identify common fundamental pathways that can be transferred to other disease entities with similar manifestations.
The Proceedings on Cancer-Immuno-Oncology offers the opportunity to publish emerging technologies, sharing experience, evaluate developments and future necessities in immuno oncology across industry and academia, and influence next-generation immunotherapy programs. The Proceedings aims to bring together and enlighten the different major fields of microbiota, new targets, liquid biopsies, new ideas of players in the immune response, new therapeutic strategies, new combinatorial approaches bringing together some of the many different ways to unravel the immune systems own power in elimination of cancer cells.